Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients

Extensive Clinical Trial Experiences of Multiple Sclerosis Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05503524

Enrollment

500

Registered

2022-08-16

Start date

2024-09-30

Completion date

2026-09-30

Last updated

2024-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Sclerosis

Brief summary

Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups. This study will admit a wide range of data on the clinical trial experience of Multiple Sclerosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Multiple Sclerosis patients.

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participant has a diagnosis of Multiple Sclerosis * Patient has self-identified as planning to enroll in an interventional clinical trial for Multiple Sclerosis * Patient is at least 18 years of age

Exclusion criteria

* Inability to perform regular electronic reporting * Patient does not understand, sign, and return consent form * No diagnosis of Multiple Sclerosis confirmed

Design outcomes

Primary

Measure	Time frame
Rate of patients who decide to enroll in a Multiple Sclerosis Clinical Trial	3 months
Number of patients who remain in Multiple Sclerosis clinical trial until completion	12 months

Contacts

Primary ContactMichael B Gill

bask@withpower.com415-900-4227

Outcome results